Alpha Tau Medical (DRTS) Return on Capital Employed (2022 - 2026)
Alpha Tau Medical (DRTS) posted Return on Capital Employed of 47.84% for Q1 2026, up 7.1% sequentially from 44.67% in Q4 2025, and down 219.0% YoY from 40.2% in Q1 2025.
Alpha Tau Medical (DRTS) Return on Capital Employed (2022 - 2026) Analysis & Trends
Alpha Tau Medical has reported Return on Capital Employed for 5 years, with the latest figure at 47.84% in Q1 2026.
- Quarterly Return on Capital Employed fell 219.0% year-over-year to 47.84% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 47.84% (down 219.0% YoY) and the FY2025 annual result came in at 49.51%, up 860.0% from the prior year.
- Return on Capital Employed rose to 47.84% in Q1 2026 per DRTS's latest filing, from 44.67% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 50.04% in Q1 2025 and troughed at 20.52% in Q2 2022.
- A 5-year average of 36.05% and a median of 36.21% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2025 and 2026: Return on Capital Employed soared 1382 bps in 2025, then sank 219 bps in 2026.
- Over 5 years, Return on Capital Employed stood at 27.84% in 2022, then grew by 28 bps to 35.76% in 2023, then climbed by 26 bps to 45.17% in 2024, then slipped by 1 bps to 44.67% in 2025, then grew by 7 bps to 47.84% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 47.84%, 44.67%, and 40.49% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Alpha Tau Medical | 1.32 Bn | 1.32 Bn | - | 30.52% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 30.52% |
| Mar 31, 2026 | 47.84% |
| Dec 31, 2025 | 44.67% |
| Sep 30, 2025 | 40.49% |
| Jun 30, 2025 | 42.74% |
| Mar 31, 2025 | 50.04% |
| Dec 31, 2024 | 45.17% |
| Sep 30, 2024 | 41.03% |
| Jun 30, 2024 | 39.17% |
| Mar 31, 2024 | 36.21% |
| Dec 31, 2023 | 35.76% |
| Sep 30, 2023 | 32.88% |
| Jun 30, 2023 | 29.71% |
| Mar 31, 2023 | 28.37% |
| Dec 31, 2022 | 27.84% |
| Sep 30, 2022 | 23.74% |
| Jun 30, 2022 | 20.52% |
| Mar 31, 2022 | 26.69% |